NASDAQ:TRVN

Trevena Competitors

$1.86

-0.39 (-17.33 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$1.64

Now: $1.86▼

$2.19

50-Day Range

$1.71

MA: $1.97▼

$2.25

52-Week Range

$0.61

Now: $1.86▼

$3.68

Volume13.68 million shs

Average Volume3.49 million shs

Market Capitalization$299.97 million

P/E RatioN/A

Dividend YieldN/A

Beta2.59

Trevena (NASDAQ:TRVN) Vs. CDMO, PTGX, PHAT, MRSN, NKTX, and YMAB

Should you be buying TRVN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Trevena, including Avid Bioservices (CDMO), Protagonist Therapeutics (PTGX), Phathom Pharmaceuticals (PHAT), Mersana Therapeutics (MRSN), Nkarta (NKTX), and Y-mAbs Therapeutics (YMAB).

Trevena vs. Avid Bioservices Stock

Trevena (NASDAQ:TRVN) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Trevena and Avid Bioservices, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevena	0	1	3	0	2.75
Avid Bioservices	0	0	3	0	3.00

Trevena currently has a consensus target price of $5.00, indicating a potential upside of 168.82%. Avid Bioservices has a consensus target price of $17.3333, indicating a potential downside of 9.53%. Given Trevena's higher possible upside, equities analysts plainly believe Trevena is more favorable than Avid Bioservices.

Institutional & Insider Ownership

11.6% of Trevena shares are held by institutional investors. Comparatively, 58.2% of Avid Bioservices shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Comparatively, 1.7% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Trevena has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500.

Profitability

This table compares Trevena and Avid Bioservices' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	-42.49%	-34.83%
Avid Bioservices	0.20%	0.31%	0.13%

Earnings and Valuation

This table compares Trevena and Avid Bioservices' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$30,000.00	9,998.99	$-24,870,000.00	($0.27)	-6.89
Avid Bioservices	$59.70 million	19.52	$-10,470,000.00	($0.27)	-70.96

Avid Bioservices has higher revenue and earnings than Trevena. Avid Bioservices is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Summary

Avid Bioservices beats Trevena on 7 of the 12 factors compared between the two stocks.

Trevena vs. Protagonist Therapeutics Stock

Protagonist Therapeutics (NASDAQ:PTGX) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Protagonist Therapeutics and Trevena, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0	0	7	0	3.00
Trevena	0	1	3	0	2.75

Protagonist Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 43.13%. Trevena has a consensus price target of $5.00, indicating a potential upside of 168.82%. Given Trevena's higher probable upside, analysts plainly believe Trevena is more favorable than Protagonist Therapeutics.

Institutional & Insider Ownership

97.5% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 11.6% of Trevena shares are owned by institutional investors. 14.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Protagonist Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Trevena has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500.

Profitability

This table compares Protagonist Therapeutics and Trevena's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-252.03%	-54.00%	-35.38%
Trevena	N/A	-42.49%	-34.83%

Valuation and Earnings

This table compares Protagonist Therapeutics and Trevena's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$230,000.00	5,056.97	$-77,190,000.00	($2.98)	-8.91
Trevena	$30,000.00	9,998.99	$-24,870,000.00	($0.27)	-6.89

Trevena has lower revenue, but higher earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Summary

Trevena beats Protagonist Therapeutics on 9 of the 14 factors compared between the two stocks.

Trevena vs. Phathom Pharmaceuticals Stock

Phathom Pharmaceuticals (NASDAQ:PHAT) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Phathom Pharmaceuticals and Trevena, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1	0	4	0	2.60
Trevena	0	1	3	0	2.75

Phathom Pharmaceuticals presently has a consensus price target of $53.00, indicating a potential upside of 43.20%. Trevena has a consensus price target of $5.00, indicating a potential upside of 168.82%. Given Trevena's stronger consensus rating and higher probable upside, analysts plainly believe Trevena is more favorable than Phathom Pharmaceuticals.

Valuation and Earnings

This table compares Phathom Pharmaceuticals and Trevena's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	N/A	N/A	$-255,130,000.00	($13.98)	-2.65
Trevena	$30,000.00	9,998.99	$-24,870,000.00	($0.27)	-6.89

Trevena has higher revenue and earnings than Phathom Pharmaceuticals. Trevena is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Phathom Pharmaceuticals and Trevena's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	N/A	-88.73%	-69.04%
Trevena	N/A	-42.49%	-34.83%

Institutional & Insider Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.6% of Trevena shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Phathom Pharmaceuticals has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Trevena has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500.

Summary

Trevena beats Phathom Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Trevena vs. Mersana Therapeutics Stock

Trevena (NASDAQ:TRVN) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Trevena and Mersana Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevena	0	1	3	0	2.75
Mersana Therapeutics	0	2	5	0	2.71

Trevena currently has a consensus target price of $5.00, indicating a potential upside of 168.82%. Mersana Therapeutics has a consensus target price of $26.1667, indicating a potential upside of 57.16%. Given Trevena's stronger consensus rating and higher probable upside, analysts clearly believe Trevena is more favorable than Mersana Therapeutics.

Valuation & Earnings

This table compares Trevena and Mersana Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$30,000.00	9,998.99	$-24,870,000.00	($0.27)	-6.89
Mersana Therapeutics	$42.12 million	27.29	$-28,210,000.00	($0.65)	-25.62

Trevena has higher earnings, but lower revenue than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Trevena and Mersana Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	-42.49%	-34.83%
Mersana Therapeutics	-8,772.91%	-45.16%	-37.53%

Institutional and Insider Ownership

11.6% of Trevena shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Comparatively, 5.3% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Trevena has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500.

Summary

Trevena beats Mersana Therapeutics on 11 of the 14 factors compared between the two stocks.

Trevena vs. Nkarta Stock

Trevena (NASDAQ:TRVN) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Trevena and Nkarta, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevena	0	1	3	0	2.75
Nkarta	0	0	5	0	3.00

Trevena currently has a consensus target price of $5.00, indicating a potential upside of 168.82%. Nkarta has a consensus target price of $59.00, indicating a potential upside of 69.20%. Given Trevena's higher probable upside, analysts clearly believe Trevena is more favorable than Nkarta.

Valuation & Earnings

This table compares Trevena and Nkarta's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$30,000.00	9,998.99	$-24,870,000.00	($0.27)	-6.89
Nkarta	N/A	N/A	N/A	N/A	N/A

Nkarta has lower revenue, but higher earnings than Trevena.

Profitability

This table compares Trevena and Nkarta's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	-42.49%	-34.83%
Nkarta	N/A	N/A	N/A

Institutional and Insider Ownership

11.6% of Trevena shares are held by institutional investors. Comparatively, 77.1% of Nkarta shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Nkarta beats Trevena on 5 of the 8 factors compared between the two stocks.

Trevena vs. Y-mAbs Therapeutics Stock

Trevena (NASDAQ:TRVN) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Trevena and Y-mAbs Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevena	0	1	3	0	2.75
Y-mAbs Therapeutics	0	2	6	0	2.75

Trevena currently has a consensus target price of $5.00, indicating a potential upside of 168.82%. Y-mAbs Therapeutics has a consensus target price of $58.1429, indicating a potential upside of 121.75%. Given Trevena's higher probable upside, analysts clearly believe Trevena is more favorable than Y-mAbs Therapeutics.

Valuation & Earnings

This table compares Trevena and Y-mAbs Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$30,000.00	9,998.99	$-24,870,000.00	($0.27)	-6.89
Y-mAbs Therapeutics	N/A	N/A	$-81,030,000.00	($2.30)	-11.40

Trevena has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Trevena and Y-mAbs Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	-42.49%	-34.83%
Y-mAbs Therapeutics	N/A	-74.98%	-66.70%

Institutional and Insider Ownership

11.6% of Trevena shares are held by institutional investors. Comparatively, 53.2% of Y-mAbs Therapeutics shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Comparatively, 38.4% of Y-mAbs Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Trevena has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Summary

Trevena beats Y-mAbs Therapeutics on 8 of the 11 factors compared between the two stocks.